EnteroMedics obesity device gets venture financing

07/20/2006 | Twincities.com

EnteroMedics received $45.2 million in venture capital to develop clinical trials for its neuromodulation implant to spur weight loss in obese people, which the company aims to have ready in two to three years. The device is designed to block the vagus nerve, controlling the feeling of hunger and slowing digestion, which differs from the approach in Medtronic's and Cyberonics' devices, which work by stimulating the nerve to mimic the feeling of being full.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations